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ABSTRACT The aim of this article was to review the role of noninvasive ventilation (NIV) in acute
pulmonary infectious diseases, such as severe acute respiratory syndrome (SARS), H1N1 and tuberculosis,
and to assess the risk of disease transmission with the use of NIV from patients to healthcare workers.
We performed a clinical review by searching Medline and EMBASE. These databases were searched for
articles on ‘‘clinical trials’’ and ‘‘randomised controlled trials’’. The keywords selected were non-invasive
ventilation pulmonary infections, influenza-A (H1N1), SARS and tuberculosis. These terms were cross-
referenced with the following keywords: health care workers, airborne infections, complications, intensive
care unit and pandemic. The members of the International NIV Network examined the major results
regarding NIV applications and SARS, H1N1 and tuberculosis. Cross-referencing mechanical ventilation
with SARS yielded 76 studies, of which 10 studies involved the use of NIV and five were ultimately selected
for inclusion in this review. Cross-referencing with H1N1 yielded 275 studies, of which 27 involved NIV. Of
these, 22 were selected for review. Cross-referencing with tuberculosis yielded 285 studies, of which 15
involved NIV and from these seven were selected. In total 34 studies were selected for this review.
NIV, when applied early in selected patients with SARS, H1N1 and acute pulmonary tuberculosis
infections, can reverse respiratory failure. There are only a few reports of infectious disease transmission
among healthcare workers.
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Introduction
Noninvasive ventilation (NIV) as an early option in selected contagious patients with severe acute
respiratory syndrome (SARS), H1N1 and tuberculosis (TB) infections that can avert or reverse respiratory
failure and, therefore, decrease complications when implemented in units with well-trained staff. Currently,
there are only a few reports of infectious disease transmission among healthcare workers. Practical
precautions and protocols to protect healthcare workers during NIV use in high-risk pulmonary infections
are necessary.
NIV is an essential component in both emergency and intensive care medicine [1]. In the 1950s, the
widespread use of the iron lung during the polio epidemic increased the survival of patients with respiratory
failure [2, 3]. Although the use of NIV and the number of articles on NIV have been rapidly growing over
the past decades [3–5], there are still insufficient data concerning the use of NIV during pulmonary
infections, especially in pandemic respiratory infections. NIV was used in patients with SARS in 2002–2003
and also during the H1N1 epidemic in 2009. However, in recent years NIV use has been extended to
patients with respiratory failure due to a wide spectrum of infectious diseases. These include, but are not
limited to, SARS and pandemic avian influenza (H5N1). However, some concern has been raised with the
use of NIV in patients with contagious diseases. Studies from Mexico, Canada, Spain, and Australia have
reported experiences with treating H1N1 influenza patients with respiratory failure [5, 6]. A significant
proportion of these patients were treated with NIV. There were no reports of disease transmission with the
use of NIV from patients to healthcare workers in these studies, but all involved healthcare workers were not
routinely screened for infection. Nevertheless, the World Health Organization (WHO) has included NIV
among aerosol-generating procedures in which the risk of pathogen transmission is possible [7, 8].
The aim of our study was to conduct a systematic review to determine the effectiveness of NIV in high-risk
pulmonary infections, including pandemic infections, and to explore the risk of infectious spread among
healthcare workers with the use of NIV. In order to perform this review, we formed an international
working group comprised of experts in infectious pathology and NIV from Asia, Europe, Latin America and
the USA. This network is a permanent working group that evaluates technological implications concerning
NIV for future pandemics and mass disaster causalities. We selected key topics related to pertinent
methodological and technical issues in NIV and infectious diseases. Our study centred on the use of NIV in
pulmonary infections, especially during pandemics, to determine the risk of transmission of infection to
healthcare workers. The international members of this network participated in the careful review of selected
studies in order to provide recommendations for protocols and guidelines, and subsequently to the writing
of this manuscript.
We conducted a search in Medline (PubMed) for published randomised and non-randomised control trials,
as well as observational studies (cohort, case–control or case series) in adult patients between January 1990
and March 2012, and in EMBASE from 1966 to June 2012.
The keywords selected were: non-invasive ventilation, pulmonary infections, influenza A (H1N1), SARS and
tuberculosis. These terms were cross-referenced with the following keywords: health care workers, airborne
infections, complications, intensive care unit and pandemic. Bibliographies of the selected articles were
hand searched for additional relevant articles. We did not include paediatric studies.
Effectiveness of NIV in pulmonary infections and pandemics
NIV in SARS
SARS, caused by the novel coronavirus (SARS-CoV), emerged in November 2002 and was first identified by
the WHO in mid-March 2003. SARS is a severe and progressive disease with ,25% of patients developing
respiratory failure [9].
In order to reduce endotracheal intubation (ETI) and its associated complications, NIV was commonly
employed in the SARS outbreak in China, including Hong Kong. The use of NIV has become part of the
standard treatment protocol for SARS [10]. A summary of clinical studies and corresponding
recommendations are described in table 1.
NIV does not demonstrate absolute benefit among non-chronic obstructive pulmonary disease (COPD)
patients with acute hypoxaemic respiratory failure or acute respiratory distress syndrome (ARDS), e.g. in
SARS patients [8, 9, 11–17]. It is well known that ETI is associated with higher risk of disease transmission
and associated complications. The use of NIV as initial ventilator support for respiratory failure in the
presence of SARS appears to be a reasonable option, albeit under strict infection control measures.
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NIV in influenza A H1N1 infection
Pandemic influenza A (pH1N1) is a new strain of influenza virus that was first identified in Mexico and the
USA in the early part of 2009 [18–30]. The pH1N1 virus originated from the swine influenza (H1N1) virus
circulating in North American pigs [23].
Animal studies have shown that the novel influenza virus caused increased morbidity and replicated to
higher titers in lung tissue; thus, explaining its pathogenicity and ability to invade the lower respiratory tract
in humans, resulting in rapid and fulminant respiratory failure [19]. Such clinical deterioration is
characterised by sudden and rapidly progressive respiratory failure with persistent and refractory hypoxia,
bilateral diffuse pulmonary infiltrates and a low arterial oxygen tension (PaO2)/inspiratory oxygen fraction
(FIO2) ratio reaching ARDS criteria [20–22, 25, 26, 31, 32]. Severe respiratory failure is common during the
first week and the incidence decreases over time. Refractory hypoxia was the major cause of death, followed
by multi-organ failure and shock [26–28, 32].
About 10–30% of hospitalised patients required admission to the intensive care unit (ICU) during the
pH1N1 epidemic [27, 28, 32]. Comorbidities were noted in 32–84% of cases admitted to the ICU. These
included obesity, COPD, diabetes mellitus, asthma, immunosuppression, chronic kidney disease and heart
failure [27–30, 32]. The overall ICU mortality rate for critically ill cases of pH1N1 was close to 17% [19–33].
Factors that were independently associated with mortality included requirement for invasive mechanical
ventilation (IMV) and a low PaO2/FIO2 ratio at ICU admission, the presence of comorbidities and older age
[19, 20, 22, 23]. Autopsy findings showed three distinct pulmonary pathologies: diffuse alveolar damage,
necrotising bronchiolitis, and diffuse alveolar damage with alveolar haemorrhage [21, 23, 24, 31]. If we
analyse ventilatory management, IMV with lung protective ventilatory strategy and fluid restriction is
recommended as the initial approach for managing patients with pH1N1 infection complicated by ARDS
[21, 24, 26, 27, 32, 33].
Based on the guidelines from the European Respiratory Society (ERS)/European Society of Intensive Care
Medicine (ESICM), WHO, the UK National Health Service, Hong Kong Lung Foundation and the
American Association for Respiratory Care (AARC), NIV is not to be used as first-line therapy in pH1N1-
associated respiratory failure for the following reasons. 1) Poor clinical efficacy in severe respiratory failure
that rapidly progresses to refractory hypoxaemia and ARDS. 2) The prevalent pattern of hypoxaemic failure
instead of hypercapnic respiratory failure in patients with pH1N1. 3) Concern about aerosol droplet particle
dispersion and spread of infection [10, 19, 34, 35].
A summary of published studies on NIV in pH1N1 is shown in table 2 [19–33, 36–48]. Of the 22 studies
included in table 2, the majority were case series reports. The contribution to pH1N1 case series according
to country is shown in table 3. There is only one international study [37] that has shown a favourable result
with the use of NIV in pH1N1. Five of the studies, most of which were case series applying a face mask for
NIV, yielded a failure rate of 10–15%. A full face mask was the NIV interface choice in all but one study; in
which the NIV helmet and face mask were used as an alternative. The results regarding the success of NIV
were highly variable. Among the causes of NIV failure are refractory hypoxaemia and shock, with multi-
organ failure being the most unfavourable. As shown in table 2, mortality is clearly lower in the group
treated with NIV versus the IMV group. While the Chinese and European studies appear to argue in favour
of NIV use, the Canadian study did not support its use. These studies do not report on significant
complications for patients and healthcare workers and in none of these studies do the authors report cases
of infection transmission to healthcare workers.
Based on the review of these reports our conclusions are as follows. NIV has a role in the management of
early respiratory failure due to pH1N1 infection; however, in a strictly controlled environment with close
monitoring of healthcare workers and with adequate precautions for prevention of infection transmission
[20, 22, 24–26, 29–33, 36–48]. NIV has no role in severe respiratory failure and ARDS related to severe
pH1N1 infection. These patients must undergo ETI and IMV [26, 30, 32, 33, 42–44, 46].
NIV in pulmonary TB
NIV remains an option for ventilatory support in both acute and chronic respiratory failure secondary to
pulmonary TB [49–54]. In acute situations, judicious use of NIV in carefully selected patients can
potentially obviate the need for IMV [49–53, 55–58]. NIV can be regarded as a simple and suitable solution
not only for the provision of long-term and domiciliary-assisted ventilation in patients with sequelae of
pulmonary TB, but also for acute exacerbations of pulmonary TB [50, 54, 59, 60]. The concern with the use
of NIV in such acute situations is linked with the potential risk of the transmission of TB [49, 56]. Whether
or not NIV should be considered a high-risk procedure in infectious diseases like TB continues to be a
controversial issue [49, 56]. However, the limited availability of invasive ventilators and/or ICU beds,
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especially in developing countries where TB incidence remains high, is an important constraint in managing
patients with TB and acute respiratory failure by means of NIV.
The medical literature offers very few published reports concerning the use of NIV in contagious TB
patients. This is due to the fact that there is a limited number of published articles where NIV was used in
exacerbations of chronic respiratory failure in patients with TB sequelae [50, 54, 59, 60], and even fewer
reports were available about the use of mechanical ventilation in acute respiratory failure due to active
pulmonary TB [56, 57].
In the seven published studies dealing with patients suffering acute exacerbations of pulmonary TB
sequelae, nasal mask was the most frequently used interface for delivery of NIV (used in four studies). These
studies suggest no apparent complications for patients and workers and report no cases of death in treated
patients. Continued applications at home following the acute phase yielded similar results. A summary of
published data on NIV in acute exacerbation of pulmonary TB is shown in table 4.
In summary, the practitioner who has to decide whether to initiate NIV or IMV in acute respiratory failure
due to pulmonary TB has to take into account several factors, such as: the prolonged period of infectiousness
of these patients; the lag time for noticeable clinical improvement following initiation of treatment; and the
risks related to positive pressure ventilation, such as pneumothorax and haemoptysis [49].
Risk of aerosol droplet generation and infection spread with NIV
Cough represents the most important airway defence reflex and one of the main symptoms of respiratory
diseases [7, 61, 62]. During coughing and sneezing, particles of mucus can be expelled to a distance of up to
9 m [14, 13, 62]. Therefore, various pathogens, when present, could infect surrounding people and animals,
thus markedly contributing to the massive dissemination of airborne infections [62]. It was shown that,
during a 3-h flight, ,80% of passengers could potentially become infected by a coughing patient with
influenza. Subsequently, these passengers could disseminate the infection at their destinations worldwide
[14, 63]. Urgent protective and therapeutic actions are considered necessary for pH1N1, SARS and TB,
which mostly affect immune-compromised populations [8, 12, 16, 47].
Currently, available recommendations are mainly based on published studies and experiences from the first
SARS epidemic in 2003 [8, 11–17]. The pivotal study arguing that NIV poses a high risk for spread of
infection is based on the assessment of particle dispersion using an experimental model. Smoke was
introduced into the lungs of a mannequin while NIV was being performed. Plumes of smoke emerging from
the vented mask were photographed for particle dispersion. As yet, there have been no studies evaluating
particle dispersion in human beings. Much debate has risen since the SARS epidemic as to whether a
mannequin-based study on particle dispersion simulates a real patient using NIV. Many experts argue that
the NIV mask may in fact offer protection from secretions that would otherwise disperse from the infected
patient during coughing, sneezing and speaking. Furthermore, there is no controlled data comparing
particle dispersion between individuals receiving NIV and those who did not [9, 62].
Guidelines from ERS/ESICM, WHO, the UK National Health Service, Hong Kong Lung Foundation and
the AARC, have considered NIV as a high-risk procedure during respiratory pandemics. This has led to
TABLE 3 Contribution to pandemic influenza A H1N1 case series (total n523) based on country
European countries n59
Spain n55
Italy n51
France n51
Portugal n51
Turkey n51
Asia n53
North America n51
Australia n51
Canada n51
Latin America n56
Mexico n52
Brazil n52
Chilean-Uruguay n51
Argentina n51
South Africa n51
North Africa (Morocco) n51
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overuse of ICU beds and strain on available resources, in addition to an increase in IMV-related
complications. Further validation of the association between NIV and infection spread by particle
dispersion is needed for planning the best strategy for future pandemics [5, 10, 19, 34, 35, 47, 63].
Technical issues should also be considered in the strategic planning of guidelines that could be used by NIV
teams for the management of suspected or proven cases of acute respiratory failure caused by contagious
diseases [34, 63]. When considering the choice of ventilators, physicians should give preference to machines
equipped with a dual-limb circuit without an unfiltered expiratory port (i.e. plateau exhalation valve,
anti-rebreathing valve, etc.) [7, 13, 18, 34, 36]. Such technology avoids the dispersion of expired air
contaminated by infected particles through a circuit leak. Such leaks are caused by bias flow necessary to
prevent rebreathing in single-limb circuits and are magnified by the high positive end-expiratory pressure
levels that are often required in the treatment of acute hypoxaemic respiratory failure [7].
A recent study reported that the use of certain standard face masks for NIV in patients with infectious
diseases might be associated with a substantial exposure to infectious organisms in the exhaled air occurring
within a distance of 1 m [7]. The dispersion of infected respiratory droplets may be amplified by an increase
in mask leakage, and can be aggravated with higher inspiratory pressures [7, 62].
Regarding interface selection, full face or total face masks might be preferred to nasal masks in order to
theoretically prevent the potential spread of contaminated exhaled air particles from unintended air leaks
through the mouth. Therefore, choosing the brand and size of mask that best fits the anatomy of the
patient’s facial contours and at the same time allows delivery of adequate pressure levels is crucial to
minimise unintended air leaks around the interface. However, currently there is no published data to
confirm this theoretical strategy as having a positive impact in clinical situations [7, 62].
Recently, in Europe, a helmet interface has become available for delivering NIV [3]. In the majority of
patients, a helmet is better tolerated than a face mask [64]. It is speculated that the use of a helmet interface,
where available, for NIV together with negative pressure rooms equipped with high-efficiency particulate air
filters, may decrease the dispersion of infected respiratory droplets.
Risk of infection spread with NIV in pandemics
During the SARS pandemic, nearly half of all SARS victims were healthcare workers, highlighting the
occupational risks associated with the care of infectious pneumonias and pandemic infections [11–14].
Evidence related to airborne transmission of the SARS virus and the potential risk of aerosol generation
with the use of NIV in SARS still remain controversial [8, 9, 11–17].
FOWLER et al. [13] examined transmission rates in healthcare workers caring for SARS patients who required
ETI and IMV. This study showed a greater risk of developing SARS in physicians and nurses performing ETI
(relative risk 13.29 (95% CI 2.99–59.04); p50.03). Although nurses caring for infected SARS patients who
are on NIV may have been at increased risk of droplet infections (RR 2.3 (95% CI 0.25–21.76)), this
theoretical health-related risk was not translated into statistically significant clinical events (p50.5). Two
other reports analysed cases of SARS in Hong Kong, China, and there were no reported cases of SARS
among healthcare workers caring for patients treated by NIV. However, it is unclear how this surveillance
was carried out [8, 12, 17, 34].
YU et al. [17] conducted a case–control study to investigate nosocomial spread of SARS by identifying
‘‘super spreading events’’ in multiple hospitals in China, including Hong Kong [8, 12, 16, 17]. The results
were of importance since 71.1% and 74.8% of the infections were attributable to super spreading events in
Hong Kong and Singapore (Malaysia), respectively. In the final multiple-logistic model, the use of NIV was
one of the six factors found to be associated with the risk of dissemination [20, 21]. However, the
significance of NIV as a contributing factor to a rapidly spreading healthcare event could not be established
[8, 12–14, 15–17].
To date, there are no reports demonstrating an increased risk of NIV-related dissemination in healthcare
workers treating infected patients [10]. During the SARS outbreak, a study performed in Hong Kong by
CHEUNG et al. [12] examined the efficacy of NIV in early ARDS and also evaluated the infection risk among
healthcare workers who had direct contact with patients on NIV. A total of 22 (25%) patients needed NIV
and a total of 155 healthcare workers, including doctors, nurses and healthcare assistants, were exposed to
these patients on NIV therapy and were regularly screened for signs of infection. Coronavirus serology was
obtained in 97% of healthcare workers. NIV equipped with expiratory bacterial and viral filters was
provided in isolated cubicles in the ward or ICU, which were centrally air-conditioned, and fitted with
exhaust ventilation fans to achieve negative pressure flow. This study concluded that NIV was not only
effective in preventing IMV in 70% of patients with acute respiratory failure due to SARS but effectively
reduced the ICU length of stay or avoided ICU admission. Moreover, no infection was noted in any of the
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155 healthcare workers. Their serology tests for coronavirus were negative. The potential risk of particle
dispersion and spread of infection due to NIV must not be overlooked, even though, at present, the data
remains inconclusive.
In pulmonary TB, the majority of patients have a relatively long period of infectiousness (weeks to months),
until the diagnosis is established and an effective anti-TB therapy is initiated [49]. There are certain
characteristics in TB patients that increase the risk for infectiousness: presence of cough, cavitation on chest
radiograph, sputum smear-positive for acid-fast bacilli, and failure to cover the mouth and/or nose during
coughing or with cough-inducing and aerosol-generating procedures [49, 50, 56, 58].
Mycobacterium tuberculosis is carried in airborne particles as droplet nuclei that can be generated when
persons with pulmonary or laryngeal TB cough, sneeze, shout or sing. The infective particles are ,1–5 mm
in diameter and are maintained in the air and spread throughout the room/building by air currents.
Therefore, TB infection is transmitted by air, not by surface contact. Contact with oculonasal secretions,
saliva or other fluids from the patient do not represent a mode of transmission of M. tuberculosis [58, 60].
High-risk infections and healthcare worker protocols
The AARC recently issued a statement concerning ventilation in mass casualty situations, including
pandemics [63]. The recommendation is against the use of NIV in pandemic influenza as the disease often
progresses to ARDS, for which NIV is not the standard of care [63]. The development of infection control
protocols for healthcare workers is essential to avoid the risk of acquiring contagious diseases [10, 18, 19, 34,
35, 49, 63, 65]. Protocols should be established in advance, before the onset of a crisis. Protocol should
TABLE 5 Summary of recommendations for noninvasive ventilation (NIV) during severe acute respiratory syndrome (SARS),
H1N1 and tuberculosis (TB) infections
Specific NIV recommendations
NIV in TB
TB patients are contagious for a relatively long period of time after starting anti-TB treatment (at least 2 weeks)
NIV needs a long period of time to improve the respiratory condition in severely ill TB patients
NIV patients are exposed to a higher risk of pneumothorax and/or haemoptysis and the lowest pressures should be set
NIV in SARS and H1N1
Selection in early stages and mild forms of ARF, such as minimal pulmonary infiltrates and arterial oxygen tension/inspiratory oxygen
fraction .250
Exclude in shock or multi-organ failure
HCW general recommendations for NIV#
TB patients with contagious forms of the disease should be isolated in airborne infection isolation (AII) rooms
Air cleaning technologies, such as HEPA filtration and UVGI, should be used
HCW entering a room with an infectious TB patient should wear at least a N95 disposable respirator (preferably a FFP3 mask)
Negative pressure rooms should be equipped with HEPA (where available) and have anterooms
Use full protective clothing as per all aerosol generating procedures including a FFP3 mask when available (N95 masks are second choice),
eye protection, a gown, gloves and an apron
Strict personal protection equipment for HCW
Minimise the number of individuals caring for the patient
Strict monitoring of HCW for signs and symptoms of infection
Equipment and setting recommendations for NIV#
Viral/bacterial filter (99.9997 efficiency)
These should be used between the mask/interface and the expiratory port, and at the outlet of the ventilator. In order to reduce the risk of
contaminating the ventilator, a bacterial filter should be placed at the expiratory side of the breathing circuit or between the mask and the
circuit. It is recommended to choose a model to filter particles 0.3 mm in size
Ventilators
Double hose tubing (inspiratory and expiratory limb) may be advantageous. Avoid high flow face mask CPAP (open exhalation port)
Interface
Helmet is preferred if applicable and available; if not, a non-vented face mask may be used
For TB patients, select long-term nasal mask ventilation
Apply and secure mask before turning on the ventilator
Pressure setting
Use the lowest possible pressures, e.g. EPAP 5 cmH2O and IPAP ,10 cmH2O titrated to respiratory rate and arterial blood gas tensions.
When applying the helmet, inspiratory pressures may be at least twice the pressures used with a standard face mask
Turn off the ventilator before removing the mask
ARF: acute respiratory failure; HCW: healthcare workers; HEPA: high-efficiency particulate air; UVGI: ultraviolet germicidal irradiation; CPAP:
continuous positive airway pressure; EPAP: expiratory positive airway pressure; IPAP: inspiratory positive airway pressure. #: these apply to SARS,
H1N1 and TB.
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include handling procedures pertaining to aerosol-generating devices such as NIV, environment, equipment
disinfection, and transport of infected patients. The designed protocol should be multidisciplinary in nature
and involve doctors, nurses, physical therapists and technical personnel [10, 18, 19, 34, 35, 49, 63, 65].
However, these protocols are not intended to supplant physician judgment with respect to special clinical
situations or individual patients. NIV must be managed under strict isolation measures in patients
suspected of or diagnosed with highly contagious infections, with adequate protection of the healthcare
workers who attend to the patient [10, 18, 19, 34, 35, 49, 63, 65].
Infected patients should be isolated in rooms with negative pressure, and visits should be restricted. The
isolation time will depend on: the period of replication of the microorganism; comorbidity of the patient,
such as immunosuppression; and availability of scientific information [10, 18, 19, 34, 35, 49, 63, 65].
Healthcare workers must wear personal protective equipment, as recommended by the Centers for Disease
Control and Prevention’s guidelines. These include N95 masks, gloves, gowns, caps, and face shields or
goggles, complemented by strict hand hygiene before and after entering the room and after managing the
patient [10, 18, 19, 34, 35, 49, 63, 65]. It is essential that the healthcare workers are familiar with NIV and
should have received adequate training for the use of NIV in contagious patients. They should also adhere
strictly to the use of personal protective equipment to avoid the risk of acquiring contagious diseases.
Recommendations for NIV in SARS, pH1N1 and TB are summarised in table 5.
Conclusion
NIV use in the management of acute respiratory failure in pulmonary infections, especially in pandemics,
can avert or reverse respiratory failure and, therefore, decrease the rate of ETI in selected groups of
contagious patients [10, 18, 19, 34, 35, 49, 63, 65]. However, its use as first-line therapy is not recommended
in severe pH1N1 infections, severe respiratory failure with ARDS or in pneumonia. Although only a few
reports have been published to date on infectious disease transmission among healthcare workers who
manage patients receiving NIV therapy, it is crucial that reasonable and adequate precautionary steps are
followed in order to protect healthcare workers from an infectious spread, as well as other patients and
family members. The International NIV Network recommends further research is conducted in this area to
determine whether currently proposed NIV protocols are effective in reducing infectious particle dispersion
and spread of disease to others.
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